Atlas Trials

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Clinical trial NCT04140487 · RECRUITING

Trial details

NCT number
NCT04140487
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative NeoplasmRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic/Myeloproliferative Neoplasm
Start date
2019-12-17
Primary completion
2028-09-01
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.